Amphetamine

An amphetamine is a chemical compound built on the alpha-methylphenethylamine scaffold — a phenethylamine bearing a methyl group on the carbon next to the amine nitrogen.^[1] The grouping is defined chemically, not by any single receptor target: a compound belongs to the class if it shares this core structure, regardless of its downstream pharmacology.

Most amphetamine-class members converge on a common pharmacological endpoint — elevated synaptic dopamine, norepinephrine, and serotonin — but the route to that endpoint differs by substitution pattern.^[3] The classical mechanism is substrate-mediated release: amphetamines enter the presynaptic terminal through monoamine transporters, disrupt vesicular storage at VMAT2, and promote reverse transport of cytosolic monoamines into the synapse. Many members additionally engage the trace-amine receptor TAAR1 and inhibit presynaptic MAO, both of which amplify cytosolic monoamine availability.^[2]

The substitution pattern determines which monoamines dominate and which downstream receptors are engaged. Unsubstituted and N-methyl amphetamines mobilize dopamine and norepinephrine with relatively little serotonin, producing a stimulant profile. A 3,4-methylenedioxy ring substitution shifts the balance toward serotonin and produces entactogenic effects. A 2,5-dimethoxy ring with a 4-position halo or alkyl substituent adds direct 5-HT_2A receptor agonism, generating psychedelic effects atop the stimulant scaffold.^[4]

The beta-keto cathinones — mephedrone, methcathinone, and the pyrrolidinyl analogues like A-PVP and MDPV — retain the alpha-methyl group but bear a carbonyl at the beta-carbon. This reduces lipophilicity and CNS penetration relative to the non-keto homologues, and for the pyrrolidinyl members shifts the mechanism from monoamine release toward reuptake inhibition.^[5]

What matters for safety is the shared endpoint rather than the particular route. Increased synaptic monoamine availability drives sympathomimetic activation, dopamine-mediated reinforcement, and — wherever serotonin release is substantial — temperature dysregulation and serotonin-syndrome risk.

The class is illustrated by members from chemically distinct subgroups, each contributing a recognisably different pharmacological character to a common scaffold.

These members differ in transporter selectivity, monoamine balance, and receptor engagement, but each carries the alpha-methyl backbone and the sympathomimetic load that follows from monoamine mobilization.

Members of the class produce a sympathomimetic baseline — raised heart rate, raised blood pressure, suppressed appetite, increased wakefulness — onto which subgroup-specific effects are superimposed.^[1]

Because the same physiological systems that produce the sought effects — catecholamine-driven arousal and monoamine release — also drive the adverse load that emerges at higher exposures, the margin between the two narrows as dose, frequency, and concurrent substances accumulate.

With repeated use the sought effects diminish through tolerance while the adverse profile — anxiety, cardiovascular burden, dysphoria following use, and mood dysregulation — tends to persist or worsen.^[6]

Beyond the cardiovascular load, two further acute hazards run across the class. Hyperthermia is a life-threatening complication particularly with the serotonin-releasing members — MDMA, MDA, MDEA, and the methylenedioxy cathinones — and is markedly amplified by physical exertion and high ambient temperature; severe cases can progress to rhabdomyolysis, acute kidney injury, and disseminated intravascular coagulation.^[8] Serotonin syndrome is a serious risk when serotonin-releasing members are combined with other serotonergic agents, including SSRIs, MAO inhibitors, and other releasers.^[9]

Combination with monoamine oxidase inhibitors is acutely life-threatening for any member of the class — the additive monoamine accumulation can produce hypertensive crisis, serotonin syndrome, or both. PMA and PMMA inhibit MAO themselves, which makes combinations with other monoamine-active substances unusually dangerous and contributes to the disproportionate fatality rate documented for these compounds.^[9] There is no specific pharmacological antidote for amphetamine toxicity; emergency management is supportive.

Repeated high-dose use of the dopamine-dominant members can produce a paranoid stimulant psychosis clinically indistinguishable from acute schizophrenia. The picture typically resolves with cessation but may recur on re-exposure, and a small proportion of users develop persistent psychotic symptoms.^[10]

Tolerance & dependence

Tolerance develops rapidly across the class through dopamine receptor downregulation, transporter adaptation, and TAAR1-mediated feedback. Cross-tolerance between members is well established — prior heavy use of one amphetamine reduces the response to another.^[6]

All members that engage the dopamine reward pathway carry potential for psychological dependence, with use driven by craving and the progressive attenuation of rewarding effects. Dependence liability is highest for the dopamine-dominant stimulants — methamphetamine, amphetamine, and the pyrrolidinyl cathinones A-PVP and MDPV — meaningful but somewhat lower for entactogenic members, and lower still for the psychedelic DO-series.^[1]

The amphetamine withdrawal syndrome is neuropsychiatric rather than physiological: profound dysphoria, anhedonia, fatigue, hypersomnia, increased appetite, psychomotor slowing, and intense drug craving. Symptoms peak within a few days of cessation and largely resolve over one to two weeks, though anhedonia and mood disruption can persist longer in heavy users.^[11] Unlike depressant withdrawal, amphetamine withdrawal does not cause seizures or cardiovascular collapse — but the suicide risk during the dysphoric phase is real and warrants clinical attention.

Sustained high-dose use of the most potent dopamine-releasing members — especially methamphetamine — is associated with persistent reductions in dopamine and serotonin transporter density, with corresponding cognitive deficits in executive function, memory, and attention; partial recovery occurs with prolonged abstinence.^[10]

The amphetamine class sits within the broader phenethylamine chemical family. All amphetamines are phenethylamines, but the alpha-methyl group that defines the class confers MAO resistance and oral activity that unsubstituted phenethylamines lack.^[1]

Two child classes nest within the amphetamine grouping. The cathinones are the beta-keto subset — every cathinone is also an amphetamine, but the carbonyl at the beta-carbon alters transporter selectivity, and the pyrrolidinyl members shift toward reuptake inhibition rather than monoamine release.^[5]

The substituted amphetamines are the broader subset bearing additional ring or amine modifications beyond the bare alpha-methyl — including the DO-series psychedelics, the methylenedioxy entactogens, and the fluorinated analogues. A third child class, the substituted aminorexes, extends the scaffold further toward the oxazoline ring system.

Aminoindanes, phenylmorpholines, phenylpropenes, phenylpropylamines, and the substituted benzofurans are further sibling classes within the phenethylamine family; their members lack the alpha-methyl extension of duration and differ accordingly in pharmacokinetics and potency. The functional takeaway is structural: every amphetamine carries an alpha-methyl on the phenethylamine scaffold, and that single modification accounts for the oral activity and prolonged duration that distinguish the class from its sibling groupings.

Any compound bearing this core — whether marketed as a stimulant, an entactogen, a psychedelic, or a cathinone — inherits the sympathomimetic load and the dependence potential that come with monoamine mobilization.